Science1 distinct publisher3 min readUpdated
A survey of nearly 1,500 people found 88 percent believe a course must always be completed, and three quarters say a medical professional told them so. Duration guidance has since narrowed.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
Researchers asked almost 1,500 Americans whether a course of antibiotics should always be finished, and the majority said yes [1]. The findings, published in Open Forum Infectious Diseases, matter because the instruction most patients are carrying around is more absolute than what the evidence now supports for many common infections [2].
The specific numbers are worth sitting with. Asked to agree or disagree with "Even if you start to feel better, it is important to always finish a prescribed course of antibiotics," 88 percent agreed, and three quarters of respondents said they had received that advice from a medical professional [3]. First author Alistair Thorpe, a research assistant professor of population health sciences at the University of Utah, told Discover the team was struck that nearly nine in ten respondents held that belief [4]. The belief is roughly 13 percentage points more widespread than the share who trace it to a clinician, which means it is also circulating on its own [1].
The survey also probed preferences. For a bacterial respiratory infection such as pneumonia, participants were asked whether they would rather have a longer course of seven or more days or a shorter one of three to five days [5]. About 60 percent said they would be more comfortable with the longer course [6]. That held across almost every demographic group, with 18- to 33-year-olds the exception, showing a slight preference for the shorter option [7]. The reasoning given for longer courses was essentially insurance, including one respondent who wrote that it is "better to be Safe than Sorry" and another who wanted to be sure the infection would not recur [8]. Those preferring shorter courses cited side effects and antibiotic resistance, and were more averse to medicines generally [9].
On the science, Thorpe's position is narrower than either slogan. There is no single duration right for every infection, he said, and the broad clinical direction is the shortest course that is effective for the specific infection and patient [10]. Appropriate duration depends on diagnosis, severity, the antibiotic used, the response to treatment, and individual risk factors [11]. According to Thorpe, a much larger body of evidence now shows that for many common infections appropriately selected shorter courses work just as well while reducing unnecessary exposure and side effects, with important exceptions including tuberculosis [12]. He also reframed the historical warning: Alexander Fleming cautioned in the 1940s that using too little of the drug could let bacteria evolve resistance [13], which Thorpe describes as an important point about adequate dosage rather than evidence that every patient must complete a full course [14]. Discover notes the BMJ has carried the argument that taking antibiotics longer than necessary could itself encourage resistance [15].
None of that is a licence to stop early on your own. Thorpe's instruction is to take antibiotics exactly as prescribed and speak with a clinician before stopping or changing treatment [16], which matches CDC guidance to follow the prescription and ask a healthcare professional about questions [17]. Thorpe and colleagues argue for more nuanced messaging, and he framed the shift as a chance to show how medical science works, communicating the change transparently rather than swapping one oversimplified slogan for another [18].
The operational point for anyone who writes prescriptions: the duration decision is now a conversation, not a default. Watch whether shorter courses arrive with an explanation of why the number of days changed, because a patient told five days with no reasoning has been handed a slogan that contradicts the one they already trust.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Researchers put the question of whether patients should always finish a course of antibiotics to almost 1,500 Americans, and the majority agreed in the affirmative.
The survey findings were published in the journal Open Forum Infectious Diseases, and recent scientific evidence suggests always finishing a course may not always be the case, according to researchers.
Asked whether they agree with the statement "Even if you start to feel better, it is important to always finish a prescribed course of antibiotics," 88 percent said yes, with three quarters saying they received this advice from a medical professional.
Alistair Thorpe, first author and a research assistant professor of population health sciences at the University of Utah, told Discover: "We were struck that nearly nine in ten respondents believed it was important to always finish an antibiotic course."
Participants were asked whether they would prefer a longer (7 or more days) or shorter (3 to 5 days) course of antibiotics for a bacterial respiratory infection, such as pneumonia.
The majority, approximately 60 percent, said they would be more comfortable receiving a longer course.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
One peer-reviewed survey, relayed secondhand; clinical claims expert-attributed
The attitudinal findings rest on a published national survey of almost 1,500 US adults with concrete percentages, which is real quantitative evidence, but it reaches us through a single consumer-science article with no methodology, sampling, weighting, or funding detail. The load-bearing clinical assertion -- that a much larger body of evidence supports appropriately selected shorter courses -- is attributed to the study's first author with no trials cited, and no independent expert appears. That combination supports the survey numbers well and the clinical narrative only weakly.
Public belief still anchored to the older finish-the-course rule
The one thing the cluster measures directly is uptake of the newer duration message among US adults, and it is low: 88 percent still endorse always finishing a course, three quarters say a clinician told them so, and roughly 60 percent would prefer a longer course for a bacterial respiratory infection, with only the 18-to-33 group leaning shorter. Clinician-side adoption -- actual prescribing durations or formal guidance revisions -- is not documented anywhere in the supplied material, so the score reflects patient-side uptake only.
Mildly overstated: 'the evidence has moved on' outruns the evidence shown
The framing that finishing a course may no longer be the standard is directionally consistent with the quoted expert, but the supplied material shows no cited trials, no guidance-body change, and no prescribing data to substantiate a settled shift; the CDC line quoted in the same article still says take treatment exactly as prescribed. The article does hedge well -- naming tuberculosis as an exception, stressing that duration depends on infection and patient, and warning against swapping one slogan for another -- so the overstatement is modest rather than severe.
Study author is also the advocate for the messaging change
The only substantive incentive visible in the supplied material is that the clinical framing and the call for changed public messaging both come from the study's first author, who has a professional stake in the survey's significance; no independent voice is quoted. The publisher's own interest is a hedged consumer-health headline, and it does append a medical-advice disclaimer and a sources list. No funding, sponsorship, or commercial relationship is disclosed in the source, so this score covers only what is observable.
Survey numbers reliable; clinical shift narrative single-sourced
Confidence is moderate. The quantitative attitudinal findings are consistently and specifically reported from a peer-reviewed publication, so those claims are dependable. Everything about the state of clinical evidence, the pace of guidance change, and prescriber behaviour rests on one expert inside one publisher's article, with no second outlet, no cited trials, and no methodology detail available for cross-checking.
science
Stewardship is aimed at the wrong half: rich countries use the resistance drugs, LMICs need them1 distinct publisher
science
COVID is growing in all 50 states, and the CDC said in June where it would start1 distinct publisher
science
A phage kinase with no target list: EMBL finds one enzyme that breaks several bacterial defences1 distinct publisher
science
Feeds are triaging patients by engagement, and the proposed defence is literacy, not moderation1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 17, 2026